Aubagio® delays onset of clinically definite MS, study
Aubagio® delays onset of clinically definite MS, study
Genzyme, a Sanofi company, announced today positive top-line results from the TOPIC trial for Aubagio (teriflunomide). The trial was designed to assess whether early initiation of Aubagio (teriflunomide) in patients who experienced their first neurological symptoms consistent with Clinically Isolated Syndrome (CIS) can prevent or delay conversion to clinically definite multiple sclerosis (CDMS)..... Read More - http://www.ms-uk.org/index.cfm/aubagio
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1324 Views
-
Last post by NHE
-
- 0 Replies
- 709 Views
-
Last post by NHE
-
- 0 Replies
- 952 Views
-
Last post by NHE
-
- 0 Replies
- 2051 Views
-
Last post by frodo
-
- 0 Replies
- 1156 Views
-
Last post by frodo
-
- 1 Replies
- 912 Views
-
Last post by jimmylegs
-
- 0 Replies
- 1895 Views
-
Last post by vesta
-
- 0 Replies
- 1633 Views
-
Last post by DIM
-
- 0 Replies
- 1852 Views
-
Last post by DIM